Forløb af generalforsamlingen i Pharma Equity Group A/S
April 16, 2024 11:29 ET
|
Pharma Equity Group A/S
Forløb af generalforsamlingen i Pharma Equity Group A/S 16. april 2024Selskabsmeddelelse nr. 13 Pharma Equity Group A/S har i dag afholdt ordinær generalforsamling med følgende resultat: 1)...
Passing of the General Meeting of Pharma Equity Group A/S
April 16, 2024 11:29 ET
|
Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group A/S 16 April 2024Company Announcement no. 13 Pharma Equity Group A/S today held its Annual General Meeting with the following results: 1)...
Bestyrelsens beslutning om udstedelse af konvertible lån
April 10, 2024 08:21 ET
|
Pharma Equity Group A/S
Bestyrelsens beslutning om udstedelse af konvertible lån 10. april 2024Meddelelse nr. 12 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af yderligere konvertible lån i...
The Board of Director's decision to issue convertible loans
April 10, 2024 08:21 ET
|
Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans 10 April 2024Company Announcement no. 12 The Board of Directors of Pharma Equity Group has decided on the issuance of additional...
Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, rapporterer meget positive slutresultater fra det klinisk fase-2 studie med selskabets patenterede lægemiddelkandidat RNX-051.
April 05, 2024 05:22 ET
|
Pharma Equity Group A/S
5. april 2024 Meddelelse nr. 11 Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, rapporterer meget positive slutresultater fra det klinisk fase-2 studie med selskabets patenterede...
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
April 05, 2024 05:22 ET
|
Pharma Equity Group A/S
5 April 2024 Company Announcement No. 11 Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s...
Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S
March 25, 2024 08:06 ET
|
Pharma Equity Group A/S
25. marts 2024 Meddelelse nr. 10 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S...
Notice convening the annual general meeting in Pharma Equity Group A/S
March 25, 2024 08:06 ET
|
Pharma Equity Group A/S
25 March 2024 Announcement no. 10 Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma...
Pharma Equity Group A/S (PEG) indgår aftale med Danske Bank om udøvelse af prisstillelse (Market Maker) i PEG aktien, fondskode: DK0061155009
March 22, 2024 04:00 ET
|
Pharma Equity Group A/S
Dato: 22. marts 2024 Årets meddelelse nr. 09 Pharma Equity Group A/S (PEG) indgår aftale med Danske Bank om udøvelse af prisstillelse (Market Maker) i PEG aktien, fondskode: DK0061155009 Pharma...
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009
March 22, 2024 04:00 ET
|
Pharma Equity Group A/S
Date: 22 March 2024 Announcement of the Year No. 9 Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009 ...